$2.90
+0.09 (+3.20%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where APVO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 2 with posted results
Held by 0 tracked-famous managers · FINRA short interest 4.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AMLNCT06634394To assess the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax/azacitidine in patients with newly diagnosed AMLOpen-label · Treatment | Phase 1 | Recruiting | Drug: APVO436, Venetoclax, Azacitidine | Acute Myeloid Leukemia (AML) | 39 | Oct 2027 | ≤ 438 d | 2025-05-11 |
| Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AMLNCT04973618Safety - Incidence of Grade 3-4 AEs and SAEsOpen-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Change of strategy | Biological: APVO436 | AML | 0 | Jan 2026 | — | 2021-12-01 |
| ALG.APV-527 First-in-human StudyNCT05934539Number of participants with dose-limiting toxicities (DLTs)Open-label · Treatment | Phase 1/2 | Unknown status | Drug: ALG.APV-527 | Solid Tumor | 56 | 2024-01-01 | — | 2023-07-07 |
| Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative ColitisNCT03768219Number of subjects with adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Biological: APVO210, Placebo | Psoriasis, Ulcerative Colitis | 85 | 2020-06-30actual | — | 2021-05-19 |
| Phase 1b Safety and Efficacy Study of TRU-016NCT01644253Incidence and severity of adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Business decision | Biological: 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine | Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma | 87 | 2020-02-24actual | — | 2021-05-20 |
| Study of ES414 in Metastatic Castration-Resistant Prostate CancerNCT02262910Maximum Tolerated Dose of ES414Open-label · Treatment | Phase 1 | Completed | Biological: ES414 | Prostate Cancer | 35 | Dec 2018actual | — | 2019-08-28 |
| Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic LeukemiaNCT01188681results2017-01-06Response Per International Workshop on Chronic Lymphocytic Leukemia (IWCLL) CriteriaRandomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine, 20 mg/kg TRU-016 and bendamustine | Chronic Lymphocytic Leukemia (CLL) | 79 | Dec 2014actual | — | 2021-06-10 |
| A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent LymphomaNCT01317901results2016-10-06ResponseOpen-label · Treatment | Phase 1 | Completed | Drug: TRU-016, Bendamustine, Rituximab | B-cell Small Lymphocytic Lymphoma Recurrent | 12 | Apr 2013actual | — | 2017-06-28 |
| Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's LymphomaNCT00614042Safety and tolerability of TRU-016 administered IV in patients with CLL or NHLOpen-label · Treatment | Phase 1 | Completed | Drug: TRU-016 (anti-CD37 protein therapeutic) | Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) | 96 | Dec 2011actual | — | 2017-06-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19